New 'Living Drug' trial targets aggressive blood cancers in kids and adults
NCT ID NCT06316856
Summary
This study is testing a new type of personalized cell therapy called CD5 CAR-T for people with T-cell cancers that have come back or not responded to other treatments. Doctors will modify a patient's own immune cells (or cells from a donor) to better target and fight the cancer. The main goals are to find a safe and effective dose and to see how well the therapy works in controlling these difficult cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
-
Shanghai Liquan Hospital
RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
RECRUITINGShanghai, Shanghai Municipality, 200435, China
Conditions
Explore the condition pages connected to this study.